These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25628249)

  • 21. AIDS vaccine models: challenging challenge viruses.
    Feinberg MB; Moore JP
    Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
    [No Abstract]   [Full Text] [Related]  

  • 22. Timing of retroviral infection influences anamnestic immune response in vaccinated primates.
    Anderson DE; Singapuri A; Kang KH; Montefiori DC; Torres JV
    Viral Immunol; 2005; 18(4):689-94. PubMed ID: 16359235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates.
    Waterman PM; Kitabwalla M; Hatfield GS; Evans PS; Lu Y; Tikhonov I; Bryant JL; Pauza CD
    Viral Immunol; 2004; 17(4):545-57. PubMed ID: 15671751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primate models of AIDS vaccine development.
    Lamb-Wharton RJ; Joag SV; Stephens EB; Narayan O
    AIDS; 1997; 11 Suppl A():S121-6. PubMed ID: 9451975
    [No Abstract]   [Full Text] [Related]  

  • 25. Towards an AIDS vaccine: the role of nonhuman primates.
    Nathanson N; Mathieson BJ
    J Med Primatol; 1999; 28(4-5):146-53. PubMed ID: 10593479
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies.
    Warren JT; Dolatshahi M
    J Med Primatol; 1993; 22(2-3):203-35. PubMed ID: 8411110
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239.
    Evans DT; Bricker JE; Sanford HB; Lang S; Carville A; Richardson BA; Piatak M; Lifson JD; Mansfield KG; Desrosiers RC
    J Virol; 2005 Jun; 79(12):7707-20. PubMed ID: 15919923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies.
    Van Rompay KK
    AIDS Res Hum Retroviruses; 2012 Jan; 28(1):16-35. PubMed ID: 21902451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
    Santra S; Seaman MS; Xu L; Barouch DH; Lord CI; Lifton MA; Gorgone DA; Beaudry KR; Svehla K; Welcher B; Chakrabarti BK; Huang Y; Yang ZY; Mascola JR; Nabel GJ; Letvin NL
    J Virol; 2005 May; 79(10):6516-22. PubMed ID: 15858035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
    Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
    Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of AIDS vaccine strategies in nonhuman primates.
    Uberla K
    Med Microbiol Immunol; 2005 Aug; 194(4):201-6. PubMed ID: 15843997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.
    Del Prete GQ; Lifson JD; Keele BF
    Curr Opin HIV AIDS; 2016 Nov; 11(6):546-554. PubMed ID: 27559710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.
    Regoes RR; Longini IM; Feinberg MB; Staprans SI
    PLoS Med; 2005 Aug; 2(8):e249. PubMed ID: 16018721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress and challenges in therapies for AIDS in nonhuman primate models.
    Haigwood NL
    J Med Primatol; 1999; 28(4-5):154-63. PubMed ID: 10593480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.